Minimal residual disease monitoring in childhood acute lymphoblastic leukemia.
about
Acute lymphoblastic leukaemiaCurrent Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic LeukemiaBone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy.Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup studyProposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemiaMinimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: A Clinical Evidence Review.Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: An Economic Analysis.Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia.Predicting relapse risk in childhood acute lymphoblastic leukaemia.Risk factors for relapse in childhood acute lymphoblastic leukemia: prediction and prevention.Genomics in acute lymphoblastic leukaemia: insights and treatment implications.Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence.Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It.Excellent outcome of minimal residual disease-defined low-risk patients is sustained with more than 10 years follow-up: results of UK paediatric acute lymphoblastic leukaemia trials 1997-2003.Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia.Epidural blood patch in leukemia patient: a case report.The effect of central nervous system involvement and irradiation in childhood acute lymphoblastic leukemia: Lessons from the NOPHO ALL-92 and ALL-2000 protocols.Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.Stanniocalcin1 gene expression in patients with acute leukemia: impact on response to therapy and disease outcome.Major impact of an early bone marrow checkpoint (day 21) for minimal residual disease in flow cytometry in childhood acute lymphoblastic leukemia.Minimal residual disease detection of leukemic cells in ovarian cortex by eight-color flow cytometry.Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.Detection of minimal residual disease in childhood B-acute lymphoblastic leukemia by 4-color flowcytometry.Molecular genetic profile in BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia can further refine outcome prediction in addition to that by end-induction minimal residual disease detection.The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection.
P2860
Q24602387-CE5BFAE0-7F85-4419-BE3D-13C18236B09AQ26751269-65E11AA7-3049-47C9-8F30-8207A5D60EC1Q35102499-7EEEFC42-324E-4F7A-920E-964A8200BA74Q36182008-25FAC04B-92AA-4103-B01D-B28B66DCFA36Q36201257-55FC6E8A-D83E-494E-BBA0-EF449B0F2200Q36371093-29A28ECD-3410-4C4D-9381-760A100427C5Q36731636-D3DF4E0E-6B71-4595-8B2D-D24CA4D01682Q36731638-8E92B914-90C4-4DCE-89FC-31A589A62FEEQ37619915-4A009C4A-698B-4085-81B5-C6548DBF07A1Q38028808-AABCDCE4-A523-434A-B74F-84C349734803Q38117685-4CE6E6CC-FF86-4489-A86A-B0E2AD2ACF49Q38264774-52C4B724-83CB-42E7-888A-53F16A2531E6Q38381463-0DFD0635-819A-4F14-ABAF-7AC35F44561EQ38698520-3CD5294B-DC6F-4612-BD27-9F9315226C96Q38756821-DFA3D065-099C-4957-9522-0C9A32FCA54AQ38909642-EB86DD01-1B25-458E-9ECE-D1F4B63457F9Q39123286-98EC15ED-6D9D-4BE9-B737-C0D3B6522F5DQ39203722-948AC8EA-75AB-49FA-815F-B08236C28BCFQ40539062-D43E0439-A2A7-4428-905E-7955AE3A6D41Q40910460-A8714AF3-98B2-470A-B9A1-2225B3BB92D6Q41140906-5C69AD49-7E09-46DA-A910-EF2FC483A506Q41246402-F9CC19D1-9206-4926-863C-2974B2935FF8Q44303548-29F543A6-43D1-4B05-A5E6-250746D2A261Q44670719-A44CC3EE-2608-4C9C-BA62-9886631E7CC6Q45785426-283932AD-358B-4FFA-9A4F-5D27C2398D0BQ46176860-CA291E91-E3FF-4A4C-B201-8BF443B38A34Q48096830-248B6393-C139-42FE-9CCD-AAD2730CC2E9Q49332440-535B6787-329E-4DFA-814B-8EC50F46178BQ50678868-DCACB068-3EDF-436D-80B3-807235F48BFBQ51660064-05323546-790C-4BC4-9389-8C5BB83918C9
P2860
Minimal residual disease monitoring in childhood acute lymphoblastic leukemia.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Minimal residual disease monitoring in childhood acute lymphoblastic leukemia.
@en
type
label
Minimal residual disease monitoring in childhood acute lymphoblastic leukemia.
@en
prefLabel
Minimal residual disease monitoring in childhood acute lymphoblastic leukemia.
@en
P1476
Minimal residual disease monitoring in childhood acute lymphoblastic leukemia.
@en
P2093
Dario Campana
P304
P356
10.1097/MOH.0B013E3283543D5C
P577
2012-07-01T00:00:00Z